Different ways to deliver 12-week once-weekly TB prevention (3HP) for people living with HIV
Options for Delivery of Short-Course Tuberculosis Preventive Therapy: The 3HP Options Trial
Comparing two ways to deliver a 12-week, once-weekly TB prevention regimen to help people living with HIV complete their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11186717 on NIH RePORTER |
What this research studies
This project compares a simplified facilitated approach to the usual self-administered delivery of 3HP, a 12-week once-weekly TB prevention medicine for people living with HIV. The simplified approach adds three supports shown to help people finish treatment: stronger counseling, interactive voice reminders with check-ins for side effects, and a 99DOTS phone-based pill-tracking system. If you join, the clinic will give you the 3HP medicine and track whether you finish treatment and how the extra supports help in everyday clinic care. The work builds on an earlier trial in Uganda that showed facilitated self-administration improved completion and lowered costs.
Who could benefit from this research
Good fit: Adults living with HIV who are eligible for 3HP TB preventive therapy and receive care at one of the participating HIV clinics would be ideal candidates.
Not a fit: People without HIV, those with active tuberculosis, or anyone who cannot take isoniazid or rifapentine are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, this could help more people living with HIV finish TB preventive treatment and lower their chances of developing active TB.
How similar studies have performed: A prior randomized trial in Uganda found that facilitated self-administered 3HP achieved high completion (about 92%), so this trial expands on promising earlier results.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Cattamanchi, Adithya — University of California-Irvine
- Study coordinator: Cattamanchi, Adithya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.